Cargando…

Targeting FLT3 by Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia

Detalles Bibliográficos
Autores principales:	Chen, Lichao, Mao, Hsiaoyin, Zhang, Jianying, Chu, Jianhong, Devine, Steven, Caligiuri, Michael A, Yu, Jianhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5558867/ https://www.ncbi.nlm.nih.gov/pubmed/28496177 http://dx.doi.org/10.1038/leu.2017.147

Ejemplares similares

CS1-Specific Chimeric Antigen Receptor (CAR)-Engineered Natural Killer Cells Enhance In Vitro and In Vivo Anti-tumor Activity Against Human Multiple Myeloma
por: Chu, Jianhong, et al.
Publicado: (2013)

Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells
por: Wang, Ying, et al.
Publicado: (2018)

Targets for chimeric antigen receptor T-cell therapy of acute myeloid leukemia
por: Schorr, Christopher, et al.
Publicado: (2022)

Off-the-shelf CAR–engineered natural killer cells targeting FLT3 enhance killing of acute myeloid leukemia
por: Mansour, Anthony G., et al.
Publicado: (2023)

Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia
por: Le, Quy, et al.
Publicado: (2021)

Chimeric antigen receptor T-cell therapy in acute myeloid leukemia
por: Koedam, Jan, et al.
Publicado: (2022)

Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against FLT3-mutant acute myeloid leukemia and KMT2A-rearranged acute lymphoblastic leukemia
por: Niswander, Lisa M., et al.
Publicado: (2022)

Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia
por: Fan, Mingxue, et al.
Publicado: (2017)

Challenges and Advances in Chimeric Antigen Receptor Therapy for Acute Myeloid Leukemia
por: Marvin-Peek, Jennifer, et al.
Publicado: (2022)

Anti-CD19 chimeric antigen receptor targeting of CD19 + acute myeloid leukemia
por: Ma, Gina, et al.
Publicado: (2018)

Targeting FLT3 Mutations in Acute Myeloid Leukemia
por: El Fakih, Riad, et al.
Publicado: (2018)

Potential targeting of FLT3 acute myeloid leukemia
por: Ambinder, Alexander J., et al.
Publicado: (2020)

Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML)
por: Hofmann, Susanne, et al.
Publicado: (2019)

Current Limitations and Perspectives of Chimeric Antigen Receptor-T-Cells in Acute Myeloid Leukemia
por: Maucher, Marius, et al.
Publicado: (2021)

Chimeric Antigen Receptor T Cell Therapy in Acute Myeloid Leukemia: Trials and Tribulations
por: Garg, Swati, et al.
Publicado: (2023)

Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy
por: Yilmaz, Ahmet, et al.
Publicado: (2020)

Targeting of IL-10R on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells
por: Chen, Nianci, et al.
Publicado: (2021)

Chimeric Antigen Receptor T Cells Targeting Cell Surface GRP78 to Eradicate Acute Myeloid Leukemia
por: Yu, Wei, et al.
Publicado: (2022)

Natural Flt3Lg-Based Chimeric Antigen Receptor (Flt3-CAR) T Cells Successfully Target Flt3 on AML Cell Lines
por: Maiorova, Varvara, et al.
Publicado: (2021)

Chimeric antigen receptor T-cell therapy for acute myeloid leukemia: how close to reality?
por: Cummins, Katherine D., et al.
Publicado: (2019)

Targeting FLT3 Signaling in Childhood Acute Myeloid Leukemia
por: Sexauer, Amy N., et al.
Publicado: (2017)

Correction: Targeting of IL-10R on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells
por: Chen, Nianci, et al.
Publicado: (2022)

Disrupting autophagy in FLT3-mutant acute myeloid leukemia
por: Grant, Steven
Publicado: (2022)

FLT3 inhibitors in acute myeloid leukemia
por: Wu, Mei, et al.
Publicado: (2018)

Chimeric Antigen Receptor (CAR)-Modified Immune Effector Cell Therapy for Acute Myeloid Leukemia (AML)
por: Acharya, Utkarsh H., et al.
Publicado: (2020)

Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia
por: Laborda, Eduardo, et al.
Publicado: (2017)

Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia
por: Pillinger, Genevra, et al.
Publicado: (2015)

Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia
por: Gebru, Melat T., et al.
Publicado: (2020)

Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia
por: Driouk, Lina, et al.
Publicado: (2020)

Preclinical Targeting of Human Acute Myeloid Leukemia Using CD4-specific Chimeric Antigen Receptor (CAR) T Cells and NK Cells
por: Salman, Huda, et al.
Publicado: (2019)

Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123
por: Morgan, Michael A., et al.
Publicado: (2021)

Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia
por: Trad, Rim, et al.
Publicado: (2022)

Therapeutic Targeting of FLT3 in Acute Myeloid Leukemia: Current Status and Novel Approaches
por: Tecik, Melisa, et al.
Publicado: (2022)

Targeting FLT3 Mutation in Acute Myeloid Leukemia: Current Strategies and Future Directions
por: Fedorov, Kateryna, et al.
Publicado: (2023)

The Impact of FLT3 Mutations on the Development of Acute Myeloid Leukemias
por: Testa, Ugo, et al.
Publicado: (2013)

Clinical use of FLT3 inhibitors in acute myeloid leukemia
por: Sutamtewagul, Grerk, et al.
Publicado: (2018)

FLT3 inhibitors: clinical potential in acute myeloid leukemia
por: Hospital, Marie-Anne, et al.
Publicado: (2017)

Developments and challenges of FLT3 inhibitors in acute myeloid leukemia
por: Ge, Shuai-Shuai, et al.
Publicado: (2022)

CPX-351 in FLT3-mutated acute myeloid leukemia
por: Andrews, Claire, et al.
Publicado: (2023)

Novel AXL-targeted agents overcome FLT3 inhibitor resistance in FLT3-ITD(+) acute myeloid leukemia cells
por: Liu, Yi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_iahkckr5bucbkbh9e6acn0ov5g